17,261 trials
Allogeneic Stem Cell Transplant · Viral Infection
Primary: Number of Participants With Presence of a Toxicity — 0 Participants
Sjögren-Larsson Syndrome
Primary: Number of Participants Experiencing a Serious Adverse Event (SAE). — 0; 0 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Influenza Immunization · Healthy Volunteers
Primary: Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 1; 1; 0 Participants
Polypoidal Choroidal Vasculopathy
Primary: Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups. — 4; 24; 0; 6 Adverse events…
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 46.4; 18.0 percent change
Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Peripheral T-Cell Lymphoma
Primary: Progression-free Survival After ASCT — 0.58; 0.77; 0.62 proportion of participants
Diabetes · Obesity
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity — 5; 4; 10; 9 Participants
Leukemia · Myelodysplastic Syndrome · Non-Hodgkins Lymphoma
Primary: Progression Free Survival/PFS at 1 Year Post UCBT. — 84 percentage of participants
Glaucoma, Open-Angle · Hypertension, Ocular
Primary: Change From Baseline in Study Eye Mean Diurnal IOP at the Week 4 — -7.79; -8.28; -8.70; -7.41 mmHg — p=0.2666
Covid19
Primary: Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic…
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
Solid Tumors
Primary: Number of Participants With Dose-limiting Toxicity — 0; 8; 2; 2 Participants
Colorectal Cancer Metastatic
Primary: Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1 — 9.52 percentage of participants
Pain
Primary: Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6) — 2.36; 25.59; 30.28; 33.77 Units on a scale